NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai Impact has been developed to harness the…


Previous articleFirst Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Next articleNuminus Advances Phase 1 Trial on Proprietary Psilocybin Product